Business briefs

Feb. 06, 2013 @ 07:53 PM

Home Depot plans to hire 140 in Durham

DURHAM – The Home Depot announced Wednesday plans to hire 80,000 seasonal workers across the country during its busiest selling season - spring.

That’s 10,000 more than last year, according to a news release from the home improvement products retailer. The company said the increase is due to anticipated sales growth.

The openings include part-time to full-time jobs. The company said they’re available on a market-by-market basis based on individual store needs and geographical variance in climate.

The company is looking to hire more than 140 seasonal workers in Durham, said Katherine Ellison, a spokeswoman for Home Depot.

Many positions will be based on spring season needs such as cashiers, lot attendants, and in lawn and garden, Ellison said.

Job seekers can apply online at http://www.careers.homedepot.com/. The company has an Online Military Skills Translator that’s designed to help translate and match an applicant's military skills with positions.

Syngenta 2012 net income up 17 percent

DURHAM -- Switzerland-based Syngenta, which has its plant biotechnology research and development headquarters in the Research Triangle Park, announced Wednesday its net income was up 17 percent to about $1.9 billion.

Its sales, at $14.2 billion, were up 7 percent. CEO Mike Mack said in a news release that in crop prices in the year rose sharply as adverse weather conditions in several regions resulted in significant production shortfalls.

“The strong growth in Syngenta’s sales reflected our flexibility in providing solutions across crops and, increasingly, in addressing agronomic challenges through our integrated offers,” Mack’s statement said.

Steve Goldsmith, a spokesman for Syngenta Biotechnology Inc., said in an email the company has about 400 employees in RTP and about 700 employes in Greensboro.

Biogen Idec agrees to buy Elan’s interest in Tysabri

WESTON, Mass. – Biogen Idec announced Wednesday it has agreed to buy Elan’s interest in Tysabri to gain marketing, distribution and governance rights over the multiple sclerosis treatment.

The closing of the deal would terminate the previous collaboration agreement between the two companies, through which the worldwide profits were split in half.

The company would pay $3.25 billion to Elan on the closing of the deal, and IT would also make future contingent payments.

The transaction has been approved by the boards of both companies and is subject to a customary review processes. It’s expected to close by the end of the second quarter.

The acquisition would have little direct impact to Biogen Idec’s Research Triangle Park operations, said Mike McBrierty, a spokesman for the company.

The RTP site, which employees more than 1,050 people, manufactures Tysabri bulk substance.